Get the Stockscreener App
8.69
2.00%
0.17
After Hours:
8.82
0.13
+1.50%
Immix Biopharma Inc stock is traded at $8.69, with a volume of 1.99M.
It is up +2.00% in the last 24 hours and down -12.93% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.52
Open:
$8.63
24h Volume:
1.99M
Relative Volume:
1.22
Market Cap:
$618.64M
Revenue:
-
Net Income/Loss:
$-34.98M
P/E Ratio:
-9.4467
EPS:
-0.9199
Net Cash Flow:
$-32.77M
1W Performance:
-1.25%
1M Performance:
-12.93%
6M Performance:
+46.30%
1Y Performance:
+220.66%
1-Day Range:
$8.58
$9.3899
1-Week Range:
$8.48
$9.785
52-Week Range:
$1.94
$12.14
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.69 | 606.54M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Cash Flow - TradingKey
Immix Biopharma, Inc. Revenue Breakdown – NASDAQ:IMMX - TradingView
IMMX|Immix Biopharma Inc|Price:8.680| - TradingKey
TradingKey - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMMX|Immix Biopharma Inc|Price:9.070|Chg%:+0.550 - TradingKey
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMMX|Immix Biopharma Inc|Price:8.593|Chg%:-0.207 - TradingKey
EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses - GlobeNewswire Inc.
Immix Biopharma, Inc. (IMMX) options chain - Yahoo Finance Australia
symbol__ Stock Quote Price and Forecast - CNN
IMMX Initiated Coverage by Needham -- Rating Set to Buy - GuruFocus
Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21 - Moomoo
Fugitive doctor on run for 21 years was living as L.A. biotech exec - KTLA
Immix Biopharma drops after chief medical officer terminated - MSN
Sex offender, a fugitive for 21 years, hid in plain sight as a yacht-owning L.A. biopharma exec - Los Angeles Times
Five things for pharma marketers to know for Tuesday, July 21, 2026 - Medical Marketing and Media
IMMX Stock Drops Significantly on Chief Medical Officer News-Immix Biopharma Investors Encouraged to Contact Kehoe Law Firm, P.C. - ACCESS Newswire
Rhode Island fugitive appears to have gotten medical job while on the run - WJAR
Report: RI fugitive likely worked as biotech executive - WPRI.com
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. - GlobeNewswire
Immix Biopharma investigated for securities fra... - Pluang
Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer ArrestIMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims - TMX Newsfile
IMMX ALERT: Immix Biopharma Investigated for Securities - GlobeNewswire
Immix Biopharma exec fired following arrest after 20 years on the run - Seeking Alpha
Why is Immix Biopharma stock sliding today? By Investing.com - Investing.com Canada
Immix Biopharma stock tumbles amid fugitive CMO report By Investing.com - Investing.com India
Immix Biopharma stock tumbles amid fugitive CMO report - Investing.com
Immix Biopharma Terminates Richard Graydon in 2026 with No Material Business Impact - Minichart
Immix Biopharma (IMMX) reports Richard Graydon’s departure as immaterial event - Stock Titan
Immix Biopharma terminates Richard Graydon employment - Bitget
Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
What's going on with Immix Biopharma stock Thursday? - MSN
Immix Biopharma’s Big Run Rests On Early CAR-T Data - Finimize
Enterprise value to revenue forward of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Price to book forward of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Immix Biopharma, Inc. Financial Disclosures & SEC Filings - TradingView
Wall Street analysts think Immix Biopharma (IMMX) could surge 113.58%: Read this before placing a bet - MSN
Enterprise value to EBIT forward of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high? - MSN
Immix Biopharma Q1 2026 Earnings: Narrower Net Loss but Stock DeclinesEarnings Season Review - dars.gov.et
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Index - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2500 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 2000 Growth Benchmark - marketscreener.com
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to Russell 3000E Growth Benchmark - marketscreener.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):